ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
129.125,51
1,74%
S&P 500
5.969,34
0,35%
US Dollar vs BRL
5,8141
0,23%
Bitcoin
97.891,00
0,02%
Brent Oil
74,745
-0,03%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. PAVmed Inc (PAVM)

  7. PAVmed Inc (PAVM) Notícias

PAVM

PAVmed (PAVM)

PAVmed Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:PAVM
DataHoraFonteTítuloCódigoCompanhia
20/11/202409:56PR Newswire (US)Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA TestNASDAQ:PAVMPAVmed Inc
18/11/202410:15PR Newswire (US)Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumNASDAQ:PAVMPAVmed Inc
14/11/202410:01PR Newswire (US)PAVmed Provides Business Update and Third Quarter 2024 Financial ResultsNASDAQ:PAVMPAVmed Inc
07/11/202410:01PR Newswire (US)Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed PublicationNASDAQ:PAVMPAVmed Inc
05/11/202410:01PR Newswire (US)Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue DriversNASDAQ:PAVMPAVmed Inc
31/10/202409:31PR Newswire (US)PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024NASDAQ:PAVMPAVmed Inc
30/10/202409:31PR Newswire (US)Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024NASDAQ:PAVMPAVmed Inc
15/10/202408:51PR Newswire (US)Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA TestNASDAQ:PAVMPAVmed Inc
10/10/202408:51PR Newswire (US)PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer CareNASDAQ:PAVMPAVmed Inc
09/10/202409:01PR Newswire (US)Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual SummitNASDAQ:PAVMPAVmed Inc
08/10/202408:49PR Newswire (US)Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024NASDAQ:PAVMPAVmed Inc
01/10/202409:01PR Newswire (US)Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL PlayersNASDAQ:PAVMPAVmed Inc
24/09/202409:01PR Newswire (US)American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer TestNASDAQ:PAVMPAVmed Inc
16/09/202417:30PR Newswire (US)PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing RequirementsNASDAQ:PAVMPAVmed Inc
10/09/202408:56PR Newswire (US)Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World CongressNASDAQ:PAVMPAVmed Inc
03/09/202408:51PR Newswire (US)Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile HealthNASDAQ:PAVMPAVmed Inc
20/08/202409:16PR Newswire (US)Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and CancerNASDAQ:PAVMPAVmed Inc
13/08/202409:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PAVMPAVmed Inc
13/08/202409:16PR Newswire (US)The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal CancerNASDAQ:PAVMPAVmed Inc
13/08/202409:01PR Newswire (US)PAVmed Provides Business Update and Second Quarter 2024 Financial ResultsNASDAQ:PAVMPAVmed Inc
12/08/202417:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PAVMPAVmed Inc
12/08/202409:07PR Newswire (US)Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial ResultsNASDAQ:PAVMPAVmed Inc
08/08/202409:31PR Newswire (US)Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing EventNASDAQ:PAVMPAVmed Inc
06/08/202409:15PR Newswire (US)Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer TestingNASDAQ:PAVMPAVmed Inc
05/08/202409:15PR Newswire (US)Lucid Diagnostics to Participate in Upcoming Investor ConferencesNASDAQ:PAVMPAVmed Inc
30/07/202409:15PR Newswire (US)PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024NASDAQ:PAVMPAVmed Inc
29/07/202409:15PR Newswire (US)Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024NASDAQ:PAVMPAVmed Inc
23/07/202409:01PR Newswire (US)Lucid Diagnostics Announces Record Quarterly EsoGuard® Test VolumeNASDAQ:PAVMPAVmed Inc
11/07/202409:31PR Newswire (US)Lucid Diagnostics Launches New Corporate WebsiteNASDAQ:PAVMPAVmed Inc
02/07/202408:55PR Newswire (US)Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening PopulationNASDAQ:PAVMPAVmed Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:PAVM

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
TELB4
TELEBRAS PN
BOV
ATOM3
ATOMPAR ON
BOV
HAPV3
HAPVIDA ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados